OR WAIT null SECS
May 20, 2024
The new facility will be the company’s first to offer full manufacturing processing for antibody drug conjugates.
May 10, 2024
At CPHI NA, Rachel Harris, AstraZeneca, spoke on her work at BioPhorum to enable industry consensus and action for sustainability with drug delivery devices.
May 09, 2024
The company’s presentation at ASGCT includes preliminary data results for a child who received the gene therapy.
May 08, 2024
The company is presenting preclinical data at the American Society of Gene & Cell Therapy annual meeting that supports the potential of the company’s CAP-002 gene therapy for correcting neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations.
May 07, 2024
The two companies will combine their cell therapy platforms to develop convertibleCAR programs targeting solid tumors.
April 26, 2024
The collaboration will combine N4’s nanoparticle delivery system with SRI’s molecular guidance system.
April 19, 2024
New regulations, including those put forth by Annex 1, require many pharmaceutical manufacturers to rethink their facility designs to promote compliance.
April 05, 2024
Zevtera has been approved to treat three types of bacterial infections and has been granted Priority Review and Fast Track and Qualified Infectious Disease Product designations.
April 04, 2024
Genmab's acquisition of ProfoundBio will boost its clinical and preclinical pipeline of ADCs for targeted cancer treatment.
March 30, 2024
FDA granted fast track designation to nipocalimab, which J&J is developing for helping alloimmunized pregnant adults treat FNAIT, a rare disease that poses risk to the fetus or newborn.